Table 3.
Treatment interval according to the initial treatment modalities and stages in patients who showed RPRTs (n = 1357)
| Median interval between treatments (range Q1, Q3) (weeks) | p value | |
|---|---|---|
| Initial modality | <0.01 | |
| Resection | 14.1 (5.9, 32.7) | |
| RFA/PEI | 19.0 (7.9, 40.1) | |
| TACE | 9.3 (5.1, 22.1) | |
| EBRT | 7.9 (5.0, 16.0) | |
| Systemic chemotherapy | 7.9 (2.5, 22.5) | |
| BCLC stage | <0.01 | |
| 0 | 21.7 (9.4, 52.3) | |
| A | 16.7 (6.4, 36.4) | |
| B | 10.3 (5.1, 22.1) | |
| C | 8.0 (4.9, 19.9) | |
| mUICC | <0.01 | |
| I | 20.4 (8.0, 42.1) | |
| II | 13.9 (6.0, 32.7) | |
| III | 9.1 (5.1, 21.9) | |
| IV | 6.6 (4.6, 11.9) |
RPRTs recurring, progressing, or remaining tumors, RFA radiation frequency ablation, PEI percutaneous ethanol injection, TACE transarterial chemoembolization, EBRT external beam radiation therapy, BCLC Barcelona Clinic Liver Cancer, mUICC modified Union of International Cancer Control